Sitagliptin attenuates urease-associated phenotypes and potentiates meropenem in multidrug-resistant Gram-negative clinical isolates: a preliminary repurposing study
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Afaf Eladl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Thienamycins, Urease, Sitagliptin Phosphate. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Urease contributes to urinary tract pathogenesis and catheter encrustation, whereas metallo-β-lactamases contribute to carbapenem resistance.
Objectives
We investigated whether the dipeptidyl peptidase-4 inhibitor sitagliptin attenuates urease-associated phenotypes and potentiates meropenem against selected multidrug-resistant Gram-negative clinical isolates.
Methods
Urease-associated activity was assessed in whole-cell suspensions and crude lysates of Proteus mirabilis. Alkalinization, crystal formation in artificial urine, and catheter-associated total biomass were also examined. Meropenem potentiation was evaluated by combined-disk and chequerboard assays, and meropenem-hydrolyzing activity was measured. Relative transcript abundance was assessed by quantitative reverse-transcription PCR, and docking was used to generate structural hypotheses. Vero-cell metabolic activity was evaluated by the MTT assay.
Results
Sitagliptin (2000 µg/mL; one-eighth of its MIC) inhibited urease-associated assay signal by 53.2%–55.2% in whole-cell suspensions and crude lysates, reduced the urease-driven pH increase from 9.21 to 7.34 after 24 h, and reduced crystal-violet-stained catheter-associated biomass by 83.6%. It reduced the apparent meropenem hydrolysis signal in periplasmic extracts by 33%–55% and reduced meropenem MICs by 16- to 64-fold in combination assays, with FICI values of 0.1406–0.1875. In the Vero-cell assay, viability at 2000 µg/mL was 94.4%, and a 50% reduction in viability was not observed within the tested range. Sitagliptin exposure was associated with reduced relative transcript abundance of ureR, ureC, blaNDM, blaIMP, and blaVIM. Docking generated binding poses near catalytic metal centres.
Conclusions
In the tested preparations and isolate panel, sitagliptin attenuated urease-associated phenotypes, reduced apparent meropenem-hydrolyzing activity and potentiated meropenem, supporting its further investigation as a potential anti-virulence and antibiotic-adjuvant candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
- Department of Microbiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44519, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
ORCID-Profile: Afaf Eladl
Zitieren
APA
Eladl, A., Abbas, H. A., Abd El-Hamid, M. I., Elbaramawi, S. S., Noureldin, N. A., & Nazeih, S. I. (2026). Sitagliptin attenuates urease-associated phenotypes and potentiates meropenem in multidrug-resistant Gram-negative clinical isolates: a preliminary repurposing study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag344
Vancouver
Eladl A, Abbas HA, Abd El-Hamid MI, Elbaramawi SS, Noureldin NA, Nazeih SI. Sitagliptin attenuates urease-associated phenotypes and potentiates meropenem in multidrug-resistant Gram-negative clinical isolates: a preliminary repurposing study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag344
BibTeX
@article{Eladl2026,
author = {Eladl, Afaf and Abbas, Hisham A and Abd El-Hamid, Marwa Ibrahim and Elbaramawi, Samar S and Noureldin, Nada A and Nazeih, Shaimaa I},
title = {Sitagliptin attenuates urease-associated phenotypes and potentiates meropenem in multidrug-resistant Gram-negative clinical isolates: a preliminary repurposing study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag344}
}
EUVIMED